Annual report observation 丨 33 chemical pharmaceutical companies shift net profit

30 May by admin

Annual report observation 丨 33 chemical pharmaceutical companies shift net profit

Annual report observation 丨 33 chemical pharmaceutical companies shift net profit
Of the 75 chemical and pharmaceutical companies that have published their 2019 annual reports, Hengrui Pharmaceutical has 53.The net profit of 2.8 billion US dollars ranked first. The net profit of 42 companies such as Huahai Pharmaceutical increased, and the net profit of 33 companies in Yan’an Bikang replaced.In addition, under the influence of the continuous promotion of generic drug consistency assessment and the gradual expansion of procurement with volume, the industry’s reshuffle is imperative. Generic drug companies are overweighting R & D, and 18 companies such as Weixin Biotechnology account forThe proportion of local revenue in the same period exceeded 10%.Hengrui Medicine’s net profit53.2.8 billion Of the 75 chemical and pharmaceutical companies that have released their 2019 annual reports, 42 companies including Huahai Pharmaceuticals have seen net profit growth.Among them, the net profit growth rate of the three companies, Huahai Pharmaceutical, Tianyu and Zhendong Pharmaceutical, accelerated to 429 respectively.78%, 257.89%, 196.82%.In addition, in 2019, 33 companies in Yan’an Bikang experienced a net profit reduction of half. Yuheng Pharmaceutical, Asia-Pacific Pharmaceutical, and Shengjitang experienced the largest declines, with net profits decreasing by 2214.30%, 1095.57%, 966.43%.In terms of “monetization ability”, the industry giant Hengrui Medicine still maintains its lead, with 53 in 2019.The net profit of 2.8 billion ranks first among chemical drug companies, which means Hengrui Medicine will earn an average of 1459 per day in 2019.730,000 yuan.Hengrui Medicine stated that the achievements of innovation have contributed to the growth and growth of the company’s performance; product structure optimization and adjustment, non-anti-tumor drug products represented by surgical anesthesia and contrast agents have gradually expanded the market within various therapeutic areas, and continue to maintain rapid growthEtc. have become a key factor in net profit growth.East China Medicine, Jilin Aodong took 28.1.3 billion, 14.Net profit of 0.4 billion followed.18 companies have invested more than 10% in research and development. While the consistency evaluation of generic drugs is continuing, the centralized collection of drugs will be expanded in 2019, and the results of the second batch of national centralized collection of drugs have also been implemented.Fundamentally speaking, due to the accelerated approval of domestic drug review and evaluation and the introduction of priority review policies, the generic drug industry is facing rapid differentiation, structural upgrades, and elimination of backward production capacity. The independent innovation ability of pharmaceuticals will enable companies to compete in the future marketChina is in an advantage.Zhengda Tianqing, Qilu Pharmaceutical, Huadong Pharmaceutical and other companies all said that they will focus on high-end generic drugs and innovative drugs, adjust product structure, clean up and eliminate some low barriers and low commercial value generic drug development projects, which also makes R & D aKey areas of corporate advantage.Among the 75 chemical and pharmaceutical companies that have published their annual reports, Peking University Pharmaceuticals, ST Furen and others did not disclose any problems, 18 of the 72 companies that announced R & D expenses accounted for more than R & D investment in the same period.10%.Among them, the research and development investment of Weixin Biological, Beida Pharmaceutical and Hanyu Pharmaceutical accounted for more than 40%, 45 respectively.02%, 43.41%, 42.51%.Editor Yue Qingxiu proofreading Jia Ning drawing Li Shiyang